OncoPPi

OncoPPi maps cancer-associated protein-protein interactions (PPIs) by integrating genomic, pharmacological, clinical, and structural data to identify oncogenic PPIs and potential therapeutic targets.

Key Features:

• High-Throughput Screening Platform: Detects PPIs associated with cancer using a high-throughput experimental screening framework focused on cancer cell contexts.
• Experimental Validation in Cancer Cells: Provides experimentally validated interaction data derived from assays performed in cancer cell lines.
• Comprehensive Data Integration: Integrates genomic alterations, cellular co-localization, domain-domain interactions, pharmacological data, clinical annotations, and structural evidence into the PPI network.
• Mutual Exclusivity Analysis: Analyzes mutual exclusivity of genomic alterations across interacting proteins to inform oncogenic relationships.
• Therapeutic Connectivity Analysis: Links PPI networks with therapeutic data to highlight potential drug targets and connections between interactome components and treatments.

Scientific Applications:

• Discovery of New Biological Models: Elucidates novel PPIs involved in cancer to support development of mechanistic biological models of tumorigenesis.
• Identification of Therapeutic Targets: Maps oncogenic PPI networks to aid in pinpointing candidate targets for drug development and precision oncology.
• Understanding Oncogenic Signaling Pathways: Characterizes cancer-specific interactomes to reveal dysregulated signaling pathways driving cancer progression.

Methodology:

Applies data integration strategies combining genomic, pharmacological, clinical, and structural data and performs computational analysis of mutual exclusivity of genomic alterations and interaction parameters.